… In this review, we summarize the basic principles of immune checkpoint inhibitors in both …
may shed light on further investigation to achieve higher clinical efficacy for these inhibitors. …

… (B) The incidence of all irAE (left) following treatment with single arm immune checkpoint
inhibitors (ICI)(CTLA-4 or PD-1 and PD-L1) or combination studies and (right) grade 3–5 …

… review, we highlight the clinical success of these FDA-approved immune checkpoint inhibitors
… going forward to maximize the efficacy of immune checkpoint blockade therapy for cancer. …

… from immune checkpoint inhibitor treatment. However, mainstream initiation of immune
checkpoint … In this review, we discuss different predictive biomarkers for anti-PD-1/PD-L1 and anti-…

… In this review, we discuss current challenges and new potential approaches to implement
rationally designed clinical trials of IO drugs, particularly those targeting immune checkpoints. …

… novel class of immune checkpoint inhibitors to gain regulatory … II data under a prioritized
review process. Interim Phase III data … The FDA has accepted nivolumab for priority review with a …

Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given
as monotherapy or combination therapy have emerged as effective treatment options for …

… review the emerging clinical and pre-clinical data identifying novel mechanisms of innate
and acquired resistance to immune checkpoint inhibition… Immune checkpoint inhibitor therapy …

… Immune checkpoint inhibitors are already part of oncologists’ therapeutic arsenal as … This
study reviews endocrinopathies associated to immune checkpoint inhibitors available to date. …

… to limit the efficacy of immune checkpoint inhibition. In patients who … review the current
literature related to the most common irAEs in patients treated with immune checkpoint inhibitors…